# Viatris Healthcare GmbH Company profile · Large company (from the award notice) - Legal form: GmbH - Seat: Bad Homburg, Germany Based on the notices and sources Inteliwert covers; not a complete record. Last checked 1 February 2026. ## Identifiers - Register entry: HRB 15331 As the covered sources state them. ## Track record in public tenders Awards in the covered notices over the last 36 months, per CPV division. | CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award | | --- | ---: | ---: | ---: | ---: | --- | --- | | 33 Medical equipments, pharmaceuticals and personal care products | 1 | — | 1 | 0 | 1 November 2024 | 1 November 2024 | Based on the notices and sources Inteliwert covers; not a complete record. ### Awards - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin, ATC N07CA01 für die Zeit 01.02.26 - 31.01.28 (zzgl. Verlängerungsoption 1x12 Monate)](https://inteliwert.com/tender/opp_ZFY03CS9XVVSCS4F4NG7CA1EW4/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi) Buyer: DAK-Gesundheit · Awarded: 1 February 2026 · CPV 33600000 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Nadroparin, ATC B01AB06 für die Zeit 01.11.2024 - 31.10.2026](https://inteliwert.com/tender/opp_T6MGZ2A98XEJ45GB0YJP3AX4HT/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum) Buyer: DAK-Gesundheit · Awarded: 1 November 2024 · CPV 33600000 - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Abirateron (ausgenommen Wirkstärke 500 mg), ATC L02BX03 für die Zeit 01.10.2024 - 30.09.2026](https://inteliwert.com/tender/opp_AYP81QJ1ER51X4G63KV02MYRN0/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum) Buyer: DAK-Gesundheit · Awarded: 1 October 2024 · CPV 33600000 ## Certifications and prequalification No certification or prequalification found in the covered sources. A certification missing here is unknown, not absent. ## Website and LinkedIn Not found in the indexed notices. ## Open tenders that might fit *Possible match based on public information* Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances. - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natalizumab (ATC-Code nach WHO: L04AG03)](https://inteliwert.com/tender/opp_SHXR7QH0JK1G2GWTPTB6W2R1Z9/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 30 Nov 2027, 23:58 (UTC+01:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/0784c581-77e3-4bbb-b6e6-e3d7c8f02e34), Last checked 6 Nov 2026, 23:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-02-01): [Evidence](https://inteliwert.com/tender/opp_ZFY03CS9XVVSCS4F4NG7CA1EW4/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 7 Nov 2026 - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_03H844YE07FD6XDS8TN35K6NVJ), checked 7 Nov 2026 - 3 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_ZFY03CS9XVVSCS4F4NG7CA1EW4/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 7 Nov 2026 - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Apixaban (ATC-Code nach WHO: B01AF02)](https://inteliwert.com/tender/opp_63D13ETK6NDN9CY2MJTSN5TGV7/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 30 Nov 2028, 23:58 (UTC+01:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/24f0c103-82cb-47e6-847f-ae97689ceafa), Last checked 6 Nov 2026, 23:30 (UTC+01:00) - Won a contract in CPV group 336 (2026-02-01): [Evidence](https://inteliwert.com/tender/opp_ZFY03CS9XVVSCS4F4NG7CA1EW4/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 7 Nov 2026 - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_03H844YE07FD6XDS8TN35K6NVJ), checked 7 Nov 2026 - 3 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_ZFY03CS9XVVSCS4F4NG7CA1EW4/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-abs-8-sgb-v-zum-wi), checked 7 Nov 2026 ## Is this your company? Send corrections, or ask us to remove the profile, to . You can also ask that the company never be tagged on LinkedIn. ## About this profile Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances. **Based on the notices and sources Inteliwert covers; not a complete record.** Last checked 1 February 2026. --- Page: https://inteliwert.com/company/org_03H844YE07FD6XDS8TN35K6NVJ/viatris-healthcare-gmbh Inteliwert is a product of Bandpey GmbH, an international data and AI software company in Munich, Germany, founded and led by Roozbeh Bandpey. Bandpey's products: Facthory, Emolysis, Copolly and Inteliwert. Inteliwert on LinkedIn: https://www.linkedin.com/company/intelliwert, GitHub: https://github.com/inteliwertai.